fda ends semaglutide shortage 🚨 The FDA has officially declared an end to the shortage of semaglutide, the active ingredient in the popular medications Ozempic and Wegovy. This announcement signals a significant Ozempic and Wegovy officially moved

Cells 12 , 21 (2022)

Many patients report that headaches diminish or resolve completely after the first month of therapy, suggesting an adaptation effect

January 2026 is aligning with commonly observed early-year interest in oral GLP-1 peptide options, as consumers compare different administration formats during seasonal "new year, new you" wellness behavior

Ozempic is a GLP1 receptor agonist that prompts your pancreas to release more insulin, decreases hepatic glucose production, slows digestion, and affects appetite centers in the brain

Immediate medical attention (call 999 or attend A&E) is required if experiencing: Severe chest pain or pressure, particularly if radiating to the arm, jaw, or back Sudden severe breathlessness or inability to speak in full sentences Loss of consciousness or fainting Chest pain accompanied by sweating, nausea, or feeling of impending doom New confusion or altered consciousness Contact your GP urgently or call NHS 111 for advice if you experience: Persistent palpitations, particularly with chest pain, breathlessness, or dizziness Irregular heartbeat Resting heart rate persistently elevated with symptoms New or worsening breathlessness with minimal exertion Dizziness or light-headedness that affects daily activities Routine GP review is advisable if: You notice any sustained change in heart rate after starting weight loss medication You have cardiovascular risk factors (hypertension, diabetes, high cholesterol, smoking, family history) You are taking multiple medications or supplements Before prescribing weight loss medications, healthcare professionals should conduct thorough cardiovascular assessment, including blood pressure measurement

Today, scurvy is rare in developed countries